Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cencora's Current Accrued Expense for the quarter that ended in Jun. 2026 was €2,906 Mil.
Cencora's quarterly Current Accrued Expense
increased
from Dec. 2025 (€2,328 Mil) to Mar. 2026 (€2,764 Mil) and
increased
from Mar. 2026 (€2,764 Mil) to Jun. 2026 (€2,906 Mil).
Cencora's annual Current Accrued Expense
increased
from Sep. 2023 (€2,206 Mil) to Sep. 2024 (€2,485 Mil) and
increased
from Sep. 2024 (€2,485 Mil) to Sep. 2025 (€2,542 Mil).
The historical data trend for Cencora's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of €2,906 Mil mean?
Cencora (WBO:ABC) has a Current Accrued Expense of €2,906 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cencora and its competitors.
Is Cencora's Current Accrued Expense too high?
Cencora's current Current Accrued Expense is €2,906 Mil. Overall, Cencora has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Current Accrued Expense compare to CAH and MCK?
Cencora's Current Accrued Expense of €2,906 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Distribution company?
A good Current Accrued Expense depends on the Medical Distribution industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cencora and its competitors. Cencora's current Current Accrued Expense is €2,906 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €262.96, compared to a current price of €279.90 — trading 6.4% above its estimated fair value. The current Current Accrued Expense is €2,906 Mil. Cencora's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Current Accrued Expense is €2,906 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €279.90 is trading 6.4% above its estimated GF Value™ of €262.96.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
Current Accrued Expense: €2,906 Mil
GF Value™: €262.96 vs. price of €279.90 (6.4% above fair value)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
78GF Score
Get the complete analysis for WBO:ABC
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
